Back to dashboard
CommercialCoverageMedium impact

08.00.84l, Eculizumab (Soliris®) and Related Biosimilars, Ravulizumab-cwvz (Ultomiris®) for intravenous administration

Independence Blue Cross·Hematology, Oncology, Nephrology·Pharmacy
Effective date
Apr 1, 2025
We identified it
Jun 19, 2026
Days to comply
—

Summary

Insurance policy for Eculizumab (Soliris®) and related biosimilars, Ravulizumab-cwvz (Ultomiris®) for intravenous administration has been updated for commercial plans. This affects coverage and billing for these specialty medications used to treat rare blood disorders.

Action Required

Action needed
By April 1, 2025: Billing team should review updated commercial policy for Eculizumab (Soliris®) and Ravulizumab-cwvz (Ultomiris®) at the provided URL to understand any changes to coverage criteria, prior authorization requirements, or billing procedures for these specialty IV medications. Update billing protocols accordingly.

Related policy hubs